ArticleClinical case reports2025
Takayasu Arteritis in a 55-Year-Old Woman With Prior
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Takayasu Arteritis in a 55-Year-Old Woman With PriorClinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu arteritis (TAK) is a rare large-vessel vasculitis affecting the aorta and its major branches. Although autoimmune mechanisms are central, prior mycobacterial infections have been hypothesized to contribute to the disease onset. A 55-year-old South Asian woman with a history of vitiligo and treated multibacillary leprosy presented with right upper limb claudication and absent radial pulse. Angiography demonstrated thickening and narrowing of the right subclavian artery. Based on the 2022 ACR/EULAR classification criteria, TAK was diagnosed with a cumulative score of eight. Initial immunotherapy with intravenous prednisolone and methotrexate, followed by oral leflunomide, failed to achieve clinical improvement, following which endovascular stenting was planned. This case emphasizes the potential role of prior mycobacterial infections in TAK pathogenesis and highlights the need for early recognition, comprehensive vascular imaging, and individualized management in atypical or postinfectious presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.